MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
BioSig Technologies EBITDA 2011-2026 | BSGM
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA BioSig Technologies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.7 M | -28.2 M | -27 M | -33.2 M | -58.6 M | -34.5 M | -17.2 M | -12.9 M | -11.2 M | -12 M | -7.85 M | -6.22 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.22 M | -58.6 M | -21.8 M |
Quarterly EBITDA BioSig Technologies
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.62 M | -19.8 M | -2.96 M | - | -2.92 M | -5.24 M | -3.36 M | - | -3.96 M | -10.8 M | -7.3 M | - | -6.4 M | -5.64 M | -8.01 M | - | -7.75 M | -8 M | -8.52 M | - | -13.1 M | -22.3 M | -12.8 M | - | -5.48 M | -7.98 M | -5.87 M | - | -3.15 M | -5.76 M | -2.63 M | - | -1.91 M | -3.02 M | -2.9 M | - | -1.55 M | -5.53 M | -2.31 M | - | -2.47 M | -4.43 M | -3.05 M | - | -3.94 M | -584 K | -724 K | - | -799 K | 4.26 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.26 K | -22.3 M | -5.73 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Butterfly Network
BFLY
|
-65.5 M | $ 4.19 | 5.67 % | $ 887 M |  USA |
 |
InMode Ltd.
INMD
|
86.1 M | $ 13.73 | 1.48 % | $ 887 M |  Israel |
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bruker Corporation
BRKR
|
437 M | $ 34.86 | 4.68 % | $ 5.19 K | USA |
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
-23.4 M | $ 9.51 | 5.32 % | $ 269 M | USA |
 |
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | USA |
 |
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
-4.64 M | $ 12.15 | -1.78 % | $ 1.82 B | USA |
 |
Delcath Systems
DCTH
|
898 K | $ 9.1 | 0.33 % | $ 326 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | USA |
 |
AxoGen
AXGN
|
-1.19 M | $ 31.75 | 3.15 % | $ 1.46 B | USA |
 |
Establishment Labs Holdings
ESTA
|
-32.8 M | $ 59.61 | -4.85 % | $ 1.77 B |  Costa-rica |
 |
CONMED Corporation
CNMD
|
120 M | $ 36.63 | 1.92 % | $ 1.14 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 82.02 | -0.58 % | $ 48 B | USA |
 |
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Electromed
ELMD
|
10.7 M | $ 24.49 | 5.2 % | $ 207 M | USA |
 |
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-15.2 M | $ 0.67 | 2.06 % | $ 36.5 M | USA |
 |
Aethlon Medical
AEMD
|
-9 M | $ 2.3 | 6.48 % | $ 3.59 M | USA |
 |
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.06 | 0.98 % | $ 1.25 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
70.8 M | $ 9.43 | 5.48 % | $ 726 M | USA |
 |
AdaptHealth Corp.
AHCO
|
473 M | $ 10.37 | 4.64 % | $ 1.4 B | USA |
 |
IRIDEX Corporation
IRIX
|
-8.91 M | $ 1.35 | - | $ 21.8 M | USA |
 |
IRadimed Corporation
IRMD
|
27.3 M | $ 99.2 | -0.3 % | $ 1.26 B | USA |
 |
FONAR Corporation
FONR
|
9.84 M | $ 18.34 | -0.22 % | $ 120 M | USA |
 |
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-18 M | $ 3.73 | 3.32 % | $ 139 M |  France |
 |
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 16.47 | -0.3 % | $ 386 M | USA |
 |
Inspire Medical Systems
INSP
|
64.9 M | $ 52.16 | -2.9 % | $ 1.53 B | USA |
 |
LivaNova PLC
LIVN
|
228 M | $ 63.24 | 1.69 % | $ 3.45 B |  Britain |
 |
Medtronic PLC
MDT
|
8.82 B | $ 87.17 | 1.13 % | $ 112 B | USA |
 |
Pulmonx Corporation
LUNG
|
-52.6 M | $ 1.39 | 2.21 % | $ 56.6 M | USA |
 |
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | USA |
 |
Myomo
MYO
|
-13.5 M | $ 0.71 | 0.08 % | $ 29.7 M | USA |
 |
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | USA |